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Abstract: 
Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on 
myelomonocytoid cell line P39. 
Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. 
Confirmation studies were performed using quantitative real time PCR.  
Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, 
NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations 
in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified 
and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable 
deregulations in our findings. 
Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk 
myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.
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Özet:
Amaç: Bu çalışmada, bir myelomonositoid hücre hattı olan P39 üzerinde bortezomib ve arsenik trioksidin etkilediği moleküler 
altyolları anlamayı amaçladık.
Gereç ve Yöntemler: Gen anlatım ve altyol analizleri için oligonükleotid mikroarray platformları kullanıldı. Konfirmasyon 
deneyleri kantitatif gerçek zamanlı PZR ile gerçekleştirildi.
Bulgular: Bortezomib işlenmesi, DIABLO ve bir NF-κB inhibitorü olan NF-κBIB’nin anlatım artışını ve NF-κB1, NF-κB2, 
BIRC1 genlerinin anlatım azalışını gösterdi. İki bileşiğin birlikte işlenmesi ise aynı genlerin anlatım düzensizliğini göstererek 
bortezomib’in tek başına işlenmesinin sonuçlarıyla uyum içindeydi. Özellikle, P53 hücre altyolu daha anlamlı bir değişikliğe 
uğradı ve beta estradiol geni çevresinde bir gen ağı biçimlendi. Beta estradiol, BRCA2 ve FOXA1 genlerinin düzen değişiklikleri 
bulgularımız içinde en dikkat çekicileriydi.
Sonuç: Sonuçlar proteazom inhibitörlerinin yüksek riskli myelodisplastik sendromda (MDS) olası kullanımı düşüncesini 
desteklemektedir. NF-κB, MDS’nin lösemik transformasyonunda önemli bir  düzenleyici  olarak gözlenmiştir.
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Introduction
NF-κB is defined as an important transcription factor 
in immunity, cell survival, and cancer [1,2,3]. NF-κB 
gene activation was observed in many steps such as tumor 
progression and metastasis [4,5]. Relationships between 
NF-κB and leukemia have recently been identified through 
new mutations on chronic lymphocytic leukemia and specific 
NF-κB pathway activation of multiple myeloma [6,7]. NF-κB /
Rel-blocking approaches have been proposed as antineoplastic 
strategies. Furthermore, the identification of specific kinases 
within the NF-κB activation pathway offers a selective target 
to address tailored therapies. Recent data provided a rationale 
for therapeutic approaches, which combined different 
NF-κB inhibitors in chronic myeloid leukemia patients [8]. 
NF-κB is also a nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor and it has been reported to be 
constitutively activated in the myelomonocytoid cell line P39 
[9]. Some MDS subtypes have a high risk of developing into 
acute myeloid leukemia [10]. Another gene whose expression 
levels have been reported to play a relevant prognostic role 
in MDS is WT1. Changes in the expression of the WT1 gene 
are associated with certain types of lung, prostate, breast, and 
ovarian cancer. Abnormal expression of the WT1 gene also 
occurs in leukemia. It is unclear what role the WT1 protein 
plays in the development or progression of cancer [11]. We 
decided to assess if a compound combination (bortezomib 
and arsenic trioxide) able to inactivate NF-κB would be 
also able to down-regulate the WT1 expression. Finally, we 
performed microarray and real-time quantitative PCR assays 
to understand the gene expression pathways affected by this 
treatment.
Materials and Methods
P39 cell line (DSMZ, Zellkulturen, Braunschweig, 
Germany) was grown within 48 hours in RPMI 1640 medium 
(Gibco-LT, CA, USA) under the treatment of different 
concentrations of bortezomib and arsenic trioxide (ATO) as 
previously described in our studies [12]. Cell viability was 
determined by trypan blue exclusion assay, and proliferative 
responses were assayed by a colorimetric test based on 
methyl thiazoletetrazolium bromide reduction [13]. After 
drug exposure, signs of apoptosis were evaluated by light 
microscopy and the Annexin V/propidiumcytofluorimetric 
analysis. Reactive oxygen species (ROS) production was 
evaluated by dihydrorhodamine 123 (DHR) (Molecular 
Probes, Eugene, OR, USA) and flow-cytometry assay [12]. 
Samples were also evaluated by the Human Apoptosis Panel 
(TaqMan®, Applera, Norwalk, USA). All the experiments 
were repeated at least three times. Reported values represent 
the means ± SD. The significance of differences between 
experimental conditions was determined using the 2-tailed 
Student’s t test. The level of significance was p<0.05. All above 
cell studies were performed in our laboratories, located at Pisa 
University. Microarray studies and real time PCR confirmations 
were performed at Kocaeli University. Microarray analysis 
was performed using the Whole Human Genome Oligo 
Microarray (Agilent Technologies), encompassing more than 
44,000 human DNA probes. The full list of cDNAs is available 
online (www.agilent.com). Protocols for sample preparation 
and hybridization of the mononuclear cells were adaptations 
of those in the Agilent Technical Manual. In short, first strand 
cDNA was transcribed from 300 ng of total RNA using T7-
Oligo (dT) Promoter Primer. Samples were transcribed in 
vitro and Cy-3-labeled by using a Quick-AMP labeling kit 
(Agilent Technologies). Following a further clean-up round 
(Qiagen), cRNA was fragmented into pieces ranging from 35 
to 200 bases in size. Fragmented cRNA samples (1.65 ug) 
were hybridized onto chips by means of 17 h of incubation at 65 
°C with constant rotation, followed by a two-step microarray 
wash of 1 min in two washing buffers (Agilent Technologies). 
Hybridized microarrays were scanned in a Agilent 
Technologies Scanner (model G2505B) and numerical results 
were extracted with Feature Extraction version 9.5.1.1 using 
014850_D_F_20060807 grid, GE1-v5_95_Feb07 protocol 
and GE1_QCM_Feb07 QC metric set. The microarray data 
were analyzed using Gene Spring software version 6.1 (Agilent 
Technologies, Santa Clara, CA, USA). The fold changes were 
analyzed by filtering the dataset using p-value <0.01 and a 
signal-to-noise ratio >2 for use in t-test statistical analysis. 
Additional filtering (minimum 2-fold change) was applied 
to extract the most of these genes, which were analyzed 
using Ingenuity Pathway Analysis (IPA) software (Ingenuity 
Systems, Redwood City, CA, USA). Those genes with known 
gene symbols (HUGO) and their corresponding expression 
values were uploaded into the software. Each gene symbol 
was mapped to its corresponding gene object in the Ingenuity 
Pathways Knowledge Base. Networks of these genes were 
algorithmically generated based on their connectivity and 
assigned a score. The score is a numerical value used to rank 
networks according to how relevant they are to the genes in 
the input dataset but may not be an indication of the quality 
or significance of the network. The score takes into account 
the number of focus genes in the network and the size of the 
network to approximate how relevant this network is to the 
original list of focus genes. The network identified is then 
presented as a graph indicating the molecular relationships 
between genes/gene products. Genes are represented as 
nodes, and the biological relationship between two nodes 
is represented as an edge (line). The intensity of the node 
color indicated the degree of up- or down-regulation. The 
node shapes are disclosed in corresponding figure legends. 
Canonical pathway analysis identified the pathways from 
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the IPA library of canonical pathways, which were most 
significant to the input data set. The significance of the 
association between the data set and the canonical pathway 
was determined based on two parameters: (1) A ratio of the 
number of genes from the data set that map to the pathway 
divided by the total number of genes that map to the canonical 
pathway and (2) a p-value calculated using Fischer’s exact 
test determining the probability that the association between 
the genes in the data set and the canonical pathway is due to 
chance alone. Real time PCR confirmations were performed as 
described before [12,14].
Results
Bortezomib inactivated NF-κB and exerted an anti-
proliferative (Figure 1) and pro-apoptotic effect (Figure 2) 
by blocking cell cycle in the G2 phase (Figure 3). It increased 
the release of reactive oxygen species (Figure 4) and down-
regulated the WT1 expression (Figure 5). In the untreated 
P39, 84 of the 93 genes involved in the apoptosis pathway 
and representation in the Taqman Low-Density Arrays were 
expressed. After treatment, bortezomib had up-regulated 
DIABLO and NFκBIB (NF-κB inhibitor), and down-regulated 
the NF-κB1, NF-κB2, and BIRC1, an anti-apoptotic gene 
(Figure 5). Seven gene pathways (P53, PPAR, IL6, IL2, 
hypoxia, Huntington’s disease, TLR) were found most 
significantly de-regulated in our microarray analysis.
Bortezomib and ATO combination resulted in synergistic 
anti-proliferative and pro-apoptotic effects (Figure 6). PPAR, 
P53, IL6, IL2, hypoxia, Huntington’s disease, TLR and cell 
cycle were the pathways more significantly modified in the 
the IPA analysis of our data, when P39 was co-incubated with 
bortezomib/ATO. Moreover, we observed SHC1, MLL, ITGAV, 
BCRA2, HMOX1, ICAM1, JUN, PMAP1 and beta estradiol 
genes were down-regulated whereas BRCA2, FOXA1, LY96 
and AKR1C1 genes were up-regulated. Levels and inter 
relationships were defined in Figure 7.
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Figure 1. Bortezomib exerted a significant anti-proliferative 
effect in a dose and time-dependent manner.
Figure 2. A significant increase of cell apoptotic rate was 
observed after treatment with the association of bortezomib 
(p<0.05, Fisher’s exact test). Columns, means of separate 
experiments; bars, standard deviation. Bortezomib exerted 
a significant pro-apoptotic effect (Annexin-V assay) after 48 
hours incubation period. First column (CTRL) indicates the 
control sample without bortezomib.
Figure 3. Flow cytometry analysis of accumulation of cells with 
DNA content. The apoptotic cell fraction increase required 
the simultaneous presence of bortezomib (∗p<0.05, Fisher’s 
exact test). Columns, means of three separate experiments; 
bars, SD. Bortezomib induces a cell cycle block in G2 phase. 
First columns indicate the (CTRL) control samples without 
bortezomib.
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Discussion
We have previously detected the over expressed levels of NF-
κB gene in our microarray screening studies on prostate cancer, 
papillary thyroid cancer and leukemia [12,14,15,16,17]. This 
study is our first observation about the relationship between 
dysregulated NF-κB expression levels and MDS.
P53 is a well-known cell cycle regulator and two studies 
have shown the relationship between NF-κB gene expression 
and lymphoblastic leukemia pathogenesis before [18,19]. 
Bastian et al. observed an activation of NF-κB after bortezomib 
treatment and the induction of apoptosis-related NF-κB target 
genes such as TNFαRs  after concomitant treatment, indicating 
a possible involvement of NF-κB as a proapoptotic mediator. 
These findings are not in concordance with ours about the 
bortezomib induction in a myelodysplastic cell line (P39). It 
is possible that bortezomib activity has different trigger effects 
to NF-κB deregulation on different types of leukemic cells.
Among the down-regulated genes, JUN, HSP70 and 
HSP90 would be relevant. Indeed, high levels of HSPs have 
been reported to negatively condition the overall survival 
of patients with high-risk MDS [20]. Other down-regulated 
genes were CREBBP, PMAIP1, SPP1, and some adhesion 
molecules, such as ICAM1. Even reduction of integrins could 
be a relevant effect exerted by the proteasome inhibitor due 
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Figure 6. Bortezomib and arsenic trioxide exert synergistic 
anti-proliferative and pro-apoptotic effects.
Figure 7. Significant up and down regulated gene network 
identified around genes after bortesomib+arsenic trioxide 
treatment for 48 hours to P39 cell line.
Figure 5. WT1 gene expression was observed as most down-
regulated, and BIRC1 gene expression was observed as most 
up-regulated. NF-κB gene was down-regulated while its 
inhibitor NF-κB1B gene was up-regulated. Results obtained 
after 48 hours incubation period.
Figure 4. ROS production after bortezomib treatment. Exposure 
of cells with and without bortezomib after which they were 
labeled with dihydrorhodamine 123 and analyzed by flow 
cytometry, to determine the percentage of cells displaying an 
increase in reactive oxygen species production (∗p<0.05 with 
respect to control; #p<0.05 with respect to bortezomib alone; 
Fisher’s exact test). Columns, means of at least three separate 
experiments; bars, SD. (b) Role of ROS in ATO/bortezomib-
mediated lethality in HL60 cells. Bortezomib induces a significant 
ROS production after 48 hours incubation period. First column 
(CTRL) indicates the control sample without bortezomib.
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to higher serum levels of ICAM1 that have been observed to 
be associated with high-risk MDS, negatively conditioning the 
survival [21].
Recently, Phase 1 studies indicated that bortezomib is a 
well-tolerated treatment option in acute myeloid leukemia 
[22]. Further studies should focus on the role of NF-κB and 
other pathways as key regulators to therapeutic effect of 
bortezomib in acute myeloid leukemia. Authors indicated that 
intracellular NAD∗ level represents a major determinant in 
the ability of bortezomib to induce apoptosis [23]. It is still 
unknown as to how many more pathways and gene networks 
exist on these apoptotic effects. 
Combinations of our two compounds showed gene 
expression deregulations which were in concordance with the 
bortezomib treatment alone. Especially, P53 was a pathway 
more significantly modified and same seven gene pathways 
were most significantly de-regulated. JUN and ICAM1 genes 
were found down-regulated again.
Beta estradiol, BRCA2 and FOXA1 genes were remarkable 
in our findings. ATO and bortezomib combination resulted 
in a gene network centralized around the beta estradiol gene. 
It has been previously reported that when estrogen binds its 
receptor it becomes a potent mitogen in the pathogenesis of 
mammary carcinoma and ATO specifically inhibits expression 
and signaling pathway of these receptor [24]. Here we can 
see the ATO’s downregulation effect over this gene. Besides, 
protein product of beta-estradiol leads to granulocytic 
differentiation when itself used as a compound on human 
CD34+ cells [25]. We believe that the gene network around 
beta estradiol is important to understand relationship about 
differentiation treatment by ATO on AML pathogenesis.
BRCA2 has been defined as a part of important pathway to 
prevent a subgroup of human leukemias and lymphomas that 
may involve non-random, characteristic gene rearrangements 
[26]. Upregulated levels of this pathway by the treatment of 
our compounds was an expected result. However, upregulated 
levels were extremely high as 29-fold. We found a relationship 
between BRCA2 and beta estradiol genes over FNG gene 
downregulation. FNG (Fringe) is a regulator of communication 
between lineage compartments during hematopoietic 
development [27]. We found the down regulated levels of 
beta estradiol were in a signal communication by BRCA2 
upregulation. It means that bortezomib and ATO exposure is 
effective on different anti-cancer mechanisms as ‘DNA repair’ 
or ‘cell differentiation’, in P39 cell line. 
Importance of FOXA1 gene was defined before in cell 
transcription in different mutations in acute myeloid leukemia 
and also offered as a promising prognostic marker in breast 
cancer [28,29]. Upregulated level of this gene was remarkable 
deregulation in our experiment. 
It is possible to discuss similarities and relations between 
NF-κB and these three genes mentioned above. NF-κB is 
an important transciption factor as FOXA1 and its critical 
role is well defined in multiple myeloma [30]. Homolog 
recombinations in DNA repair induction by NF-κB required 
the target BRCA2 [31]. Estrogen modulates NFeq signaling at 
the promoters of inflammatory genes via estrogen receptor-B 
[32]. We have used compounds effective to inactivate NF-
κB and these affection looks deeper when we add ATO to 
bortezomib.
Taken together, NF-κB was observed as an important 
modulator in leukemic transformation of MDS. These results 
suggest the possible use of proteasome inhibitors in treatment 
of high-risk MDS. In vivo trials will be useful to confirm 
this hypothesis. Moreover, our study was a preliminary 
observation of a cell line exposed to drug combinations and 
different leukemic cells should be studied in this manner as 
many dimensions of the studies would be discussed separately. 
This would create insight to the arising gene pathways after 
bortezomib and ATO exposure in leukemia, and their specific 
traces on networks defined on miRNA investigation and 
proteomic levels. 
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